Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05607550
Title Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors ArriVent BioPharma, Inc.
Age Groups: senior | adult
Covered Countries USA | NLD | ITA | GBR | FRA | ESP | AUS

No variant requirements are available.